Skin cancer can return after Mohs surgery, but it happens far less often than with other treatment methods. For basal cell carcinoma and squamous cell carcinoma, the two most common types treated with Mohs, recurrence rates generally stay below five percent in people with healthy immune systems. That low number, however, is not zero, and certain patient and tumor characteristics can push it meaningfully higher. Understanding what drives recurrence helps explain why follow-up care after Mohs matters and when extra vigilance is warranted.
How Often Skin Cancer Returns After Mohs
A large prospective study from the Spanish national Mohs registry tracked patients over five years and found an incidence rate of 1.3 recurrences per 100 person-years for basal cell carcinoma and 4.5 per 100 person-years for squamous cell carcinoma. Notably, the recurrence rate stayed constant across the five-year window rather than clustering in the first year or two.1PubMed Central. Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery) That steady trickle is an important detail: even if the first couple of years look clean, late recurrences are not unusual, so surveillance should not stop early.
For squamous cell carcinoma specifically, a separate multicenter study reported a five-year cumulative recurrence of about 3.3% after Mohs, which was in the same ballpark as standard excision at 1.7%, though the difference was not statistically significant once tumor stage was accounted for.2PubMed. Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study That finding may seem counterintuitive, since Mohs is generally considered the gold standard. Part of the explanation is that Mohs tends to be reserved for the harder cases, meaning the tumors treated with Mohs are often more advanced or more aggressively located from the start. Direct comparisons with standard excision therefore need to be read carefully.
A single-center review of high-risk squamous cell carcinomas treated with Mohs found a local recurrence rate of just 1.2%, but also found that three-quarters of those patients developed a separate new squamous cell carcinoma during follow-up, and nearly eight percent were later diagnosed with melanoma.3PubMed Central. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma This distinction between a recurrence at the original site and a brand-new cancer elsewhere on the body is one of the most commonly misunderstood aspects of post-Mohs care.
True Recurrence Versus New Cancers in Sun-Damaged Skin
When a patient notices a new lesion near a Mohs scar, the first instinct is to assume the cancer came back. Sometimes it did. But in many cases, what appears to be a recurrence is actually a brand-new cancer growing in the same sun-damaged neighborhood. This phenomenon, sometimes called field cancerization, describes what happens when years of UV exposure cause widespread genetic damage across an area of skin. Multiple abnormal cell populations can develop independently, so removing one tumor does not protect the surrounding field from producing another.4Springer. Updates on Treatment Approaches for Cutaneous Field Cancerization
The practical implication is that a clean Mohs result does not mean you are “cured” of skin cancer in a broader sense. You still carry the cumulative sun damage that created the first tumor. This is why dermatologists recommend ongoing full-skin checks rather than just monitoring the surgical site. And it partly explains the striking finding that 75% of high-risk squamous cell carcinoma patients developed another squamous cell carcinoma within a few years of Mohs, as mentioned above.
Tumor Characteristics That Raise the Risk
Not all skin cancers carry the same likelihood of recurrence after Mohs. Several features of the tumor itself matter considerably.
Aggressive Growth Patterns
Basal cell carcinomas come in a range of subtypes. The nodular type is the most common and generally the most straightforward to clear. But more aggressive subtypes, such as morpheaform (also called sclerosing) and infiltrating basal cell carcinoma, tend to spread beneath the skin surface in ways that are harder to track. A study examining subclinical spread found that morpheaform basal cell carcinomas were about 2.3 times as likely as nodular types to extend beyond their visible borders, while previously recurrent basal cell carcinomas were 3.2 times as likely, and previously recurrent squamous cell carcinomas were 4.2 times as likely.5JAMA Dermatology. Predictors of Extensive Subclinical Spread in Nonmelanoma Skin Cancer Treated With Mohs Micrographic Surgery
A separate concern involves tumors with mixed histology, where a single lesion contains both aggressive and non-aggressive growth patterns. If the initial biopsy only samples the less aggressive component, the treatment plan may underestimate what the surgeon is dealing with. The more aggressive portion can persist and eventually show up as what looks like a recurrence, when in reality it was never fully treated in the first place.6PubMed. Cutaneous carcinoma with mixed histology: a potential etiology for skin cancer recurrence and an indication for Mohs microscopically controlled surgical excision This is one of the reasons Mohs is particularly valuable for complex tumors: examining the entire surgical margin under the microscope catches aggressive components that a standard biopsy might miss.
Perineural Invasion
When skin cancer cells invade the tiny nerves in the skin, it changes the prognosis significantly. Perineural invasion is more common in squamous cell carcinoma and is associated with larger, more aggressive tumors.7Journal of the American Academy of Dermatology. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion Cancer cells can travel along nerve sheaths beyond the visible or palpable tumor, making complete clearance more difficult even with Mohs.
An Australian study of squamous cell carcinoma patients with perineural invasion treated by Mohs found that about half received additional radiation therapy after surgery. Among those who completed five years of follow-up, 8% were diagnosed with a recurrence.7Journal of the American Academy of Dermatology. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion That is considerably higher than the typical post-Mohs recurrence rate and explains why perineural invasion often triggers a conversation about combining Mohs with radiation. Perineural invasion of squamous cell carcinoma is also linked to increased mortality, which makes detection and aggressive treatment particularly important.8Journal of the American Academy of Dermatology. Squamous cell carcinoma of skin with perineural invasion
Location on the Face
Certain areas of the face, collectively called the H-zone, carry higher recurrence risk. This includes the nose, the area around the eyes, the ears, and the lips. Clinical guidelines specifically recommend Mohs for primary basal cell carcinomas in this zone when they are larger than one centimeter, have aggressive histology, or are already recurrent.9PubMed Central. Patient indications for Mohs micrographic surgery: a clinical practice guideline These areas pose challenges because the anatomy is complex, tissue conservation is critical for functional and cosmetic reasons, and tumors here tend to have less clear boundaries.
Why Immunosuppression Changes the Equation
People with weakened immune systems, whether from organ transplant medications, autoimmune disease treatments, or other causes, face substantially higher recurrence rates after Mohs. A nationwide prospective study found that immunosuppressed patients had a recurrence rate roughly 2.8 times that of immunocompetent patients.10PubMed. Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery) A systematic review corroborated this, noting that while recurrence rates in people with healthy immune systems typically stay below 5% for both basal cell and squamous cell carcinoma after Mohs, immunosuppressed patients can see rates up to threefold higher.11The Innovation Lab Journal. Comparative Recurrence Rates Following Mohs Micrographic Surgery in Immunosuppressed vs. Immunocompetent Patients: A Systematic Review
The immune system plays a continuous role in controlling residual abnormal cells. When that surveillance is blunted by medication, even a few cancer cells left behind or newly mutated cells in the surrounding tissue have a better chance of establishing themselves. This is why organ transplant recipients and patients on long-term immunosuppressive therapy are typically placed on more aggressive follow-up schedules after any skin cancer treatment.
When a Tumor Has Already Recurred Once
A cancer that has come back after prior treatment, whether that initial treatment was standard excision, radiation, or a destructive method, is inherently harder to deal with. Recurrent tumors treated with Mohs required more surgical stages and resulted in larger wound defects compared to primary tumors.12Acta Dermato-Venereologica. Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas Scar tissue from the original treatment can obscure the tumor’s borders, and cancer cells may have spread along irregular paths during the initial incomplete removal. The Spanish registry data confirmed that non-primary tumors (those that were recurrent or had been incompletely excised before) were at elevated risk of recurring again after Mohs.1PubMed Central. Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery)
This creates a frustrating cycle: once a cancer has recurred, the likelihood of it recurring again goes up. It is one of the strongest arguments for getting the right treatment the first time, particularly for high-risk tumors on the face. Mohs is specifically recommended for recurrent basal cell carcinoma of the face precisely because margin control is so important in this scenario.9PubMed Central. Patient indications for Mohs micrographic surgery: a clinical practice guideline
Technical Factors and Laboratory Errors
Mohs surgery depends on meticulous tissue processing and microscopic examination, and things can occasionally go wrong at the lab bench. A study examining cases where cancer recurred despite Mohs identified multiple possible causes: about a quarter of cases involved dense inflammation in the final surgical margin that may have obscured remaining tumor cells, another quarter had visible tumor that was apparently missed, and a similar proportion involved sections where epidermal or dermal tissue was missing from the slide.13Dermatologic Surgery. Laboratory Errors Leading to Nonmelanoma Skin Cancer Recurrence After Mohs Micrographic Surgery Histologic preparation has numerous steps where errors can occur, from how tissue is oriented and flattened to how it is cut and stained.14Dermatologic Clinics. Histologic Pitfalls in the Mohs Technique
Surgeon-related factors also matter. A study analyzing the relationship between surgical errors, slide quality, and tumor recurrence found that surgeon error and tissue dropout (where a portion of the tissue fails to make it onto the slide properly) were both independently significant predictors of recurrence, alongside aggressive tumor subtype.15Journal of the American Academy of Dermatology. Surgeon error and slide quality during Mohs micrographic surgery: Is there a relationship with tumor recurrence? None of this should undermine confidence in Mohs overall. The recurrence rates are still impressively low. But it is a reminder that the procedure’s success depends on the skill and attention of the team performing it, and that choosing an experienced Mohs surgeon is not a trivial decision.
Mohs for Melanoma
Most discussions of Mohs surgery focus on basal cell and squamous cell carcinoma, but the technique is also used for melanoma in situ and some invasive melanomas, particularly on the face where tissue conservation matters. When performed with special immunostaining techniques that highlight melanoma cells, the results are encouraging. One study of nearly 600 lesions found a local recurrence rate of 0.34% over an average follow-up of about 2.8 years.16PubMed. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment
A comparison of Mohs versus wide local excision for melanoma in situ found a five-year recurrence rate of about 1% after Mohs versus roughly 4% after standard wide excision, though the difference narrowly missed statistical significance.17JAMA Dermatology. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision Melanoma behaves differently from basal cell and squamous cell carcinomas. Individual melanoma cells can extend far beyond visible borders through the epidermis, which is why the specialized staining is necessary and why not all Mohs surgeons offer melanoma treatment. If you are considering Mohs for a melanoma, confirming that the surgeon uses immunostaining protocols for margin evaluation is important.
Rare Tumors and Unusual Applications
Mohs has been applied to several less common skin cancers as well. Dermatofibrosarcoma protuberans is a rare, slow-growing soft tissue tumor that is notorious for coming back after standard excision. A study of head and neck cases treated with Mohs using paraffin-embedded sections found only a single recurrence (about 2.4%) over a mean follow-up of nearly eight years, with no regional or distant relapses.18Journal of Plastic, Reconstructive & Aesthetic Surgery. Treatment of dermatofibrosarcoma of the head and neck with Mohs surgery with paraffin sections For a tumor that historically has recurrence rates of 20% or higher with conventional surgery, that is a major improvement and illustrates how Mohs can be adapted for situations beyond its most common use.
The Emotional Side of Waiting for Recurrence
The clinical data on recurrence rates are reassuring, but they do not always match how patients feel. A qualitative study of people who had undergone facial skin cancer surgery identified fear of new cancers or recurrence as one of the major psychological themes affecting patients’ lives afterward.19PubMed Central. Patient experiences and outcomes following facial skin cancer surgery: A qualitative study Even when told the odds are low, many patients experience ongoing anxiety at every follow-up visit, every new spot, or every change in skin texture near the scar.
This anxiety is not irrational. The steady recurrence rate across the full five-year window mentioned earlier means there is no clear “all clear” moment, and the high likelihood of developing a new, unrelated skin cancer compounds the psychological burden. Appearance-related concerns, social withdrawal, and the physical discomfort of recovery were also common themes. Recognizing that some degree of worry is normal, and that it often improves with time and consistent follow-up, can be helpful. For some patients, structured skin self-examination routines provide a sense of control that eases the anxiety of simply waiting.
The Cost Question When Cancer Returns
If a cancer does recur after Mohs, patients may face a decision between re-excision (often another round of Mohs) and adjuvant radiation therapy. These options differ substantially in cost. A modeled analysis comparing Mohs to superficial radiation therapy found that a Mohs procedure typically costs between about $1,000 and $1,600 depending on the repair complexity, while radiation therapy ranged from roughly $1,450 for a short course up to over $25,000 for a full 25-session regimen.20PubMed. Modeled Cost Analysis Using CPT/Medicare Rates and Approach Comparing Superficial Radiation Therapy Versus Mohs in Patients With Squamous Cell Carcinoma Radiation therapy was estimated to be anywhere from 1.1 to 23 times more expensive than Mohs regardless of repair complexity. These numbers are based on U.S. Medicare rates and vary by location and insurance, but the general picture is that re-excision with Mohs tends to be the more affordable path when surgery is still an option.
Cost is only one factor, of course. For patients who are not surgical candidates, or for tumors with perineural invasion where radiation is used as an add-on rather than a replacement, the decision depends on the clinical situation. But when both approaches are on the table, it is worth knowing that another Mohs procedure is generally less financially burdensome than a full radiation course.
What Follow-Up Looks Like After Mohs
Because recurrence can show up years after treatment, and because the risk of a completely new skin cancer is high in anyone who has already had one, ongoing monitoring is essential. Most dermatologists recommend skin checks every six to twelve months for the first few years, with the frequency adjusted based on individual risk factors like the ones discussed throughout this article: immunosuppression, aggressive histology, perineural invasion, and whether the tumor was a primary or recurrent lesion.
During follow-up visits, the dermatologist examines the surgical site for any signs of recurrence, such as a new growth within or near the scar. But the entire skin surface gets checked as well, because the risk of new unrelated skin cancers is high. Self-examination between appointments is also encouraged. Any change in the Mohs scar, new nodule, persistent redness, or non-healing area near the original site warrants an earlier visit rather than waiting for the next scheduled check. The evidence that recurrence rates stay constant over time rather than tapering off underscores that there is no safe point at which you can stop paying attention entirely.1PubMed Central. Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery)